New Edge Advisors, LLC Gain Therapeutics, Inc. Transaction History
New Edge Advisors, LLC
- $11.2 Billion
- Q1 2024
A detailed history of New Edge Advisors, LLC transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 225 shares of GANX stock, worth $292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
225Holding current value
$292% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding GANX
# of Institutions
33Shares Held
2.58MCall Options Held
22.2KPut Options Held
16K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$764,9330.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$735,9690.1% of portfolio
-
Raymond James & Associates St Petersburg, FL260KShares$338,0240.0% of portfolio
-
Royal Bank Of Canada Toronto, A6249KShares$323,0500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$230,2180.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $15.4M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...